SCHEMBL23628862

SCHEMBL23628862

COC(=O)C(C)CNc1nc(-c2ccc(-c3ccc(F)cc3)cc2)cs1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 6/20 0.51
▸ ALOX5 P09917 3/20 0.49
▸ LMNA P02545 3/20 0.48
▸ MAPK1 P28482 3/20 0.48
▸ RAB9A P51151 4/20 0.47
▸ NPC1 O15118 3/20 0.47
▸ ALDH1A1 P00352 3/20 0.47
▸ MAPT P10636 3/20 0.47
▸ SMN1; SMN2 Q16637 2/20 0.47
▸ TP53 P04637 1/20 0.47
▸ MEN1 O00255 5/20 0.47
▸ HDAC1 Q13547 1/20 0.47
▸ HDAC6 Q9UBN7 1/20 0.47
▸ HDAC9 Q9UKV0 1/20 0.47
▸ CASP3 P42574 2/20 0.46
▸ SENP7 Q9BQF6 2/20 0.46
▸ HTT P42858 2/20 0.46
▸ KDM4E B2RXH2 1/20 0.46
▸ GAA P10253 1/20 0.46
▸ TDP1 Q9NUW8 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23628809 0.88 KMT2A (0.53) KMT2AALOX5LMNAMAPK1RAB9A
SCHEMBL4590819 0.79 KMT2A (0.56) KMT2AALOX5LMNAMAPK1RAB9A
SCHEMBL28769527 0.78 ALOX5 (0.56) KMT2AALOX5LMNAMAPK1RAB9A
SCHEMBL27045678 0.77 KMT2A (0.49) KMT2AALOX5LMNAMAPK1RAB9A
SCHEMBL23628857 0.76 ALDH1A1 (0.43) KMT2ALMNANPC1ALDH1A1MAPT
SCHEMBL27045816 0.74 KMT2A (0.53) KMT2AALOX5LMNAMAPK1RAB9A
SCHEMBL27045702 0.74 LMNA (0.56) KMT2AALOX5LMNAMAPK1RAB9A
SCHEMBL4742174 0.74 KMT2A (0.59) KMT2AALOX5LMNAMAPK1RAB9A
SCHEMBL9891898 0.74 LMNA (0.69) KMT2AALOX5LMNAMAPK1RAB9A
SCHEMBL4590880 0.74 KMT2A (0.59) KMT2AALOX5LMNAMAPK1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12030875-B2 EIF4E inhibitors and uses thereof PIC Therapeutics, Inc. (US) 2024-07-09 — — US disclosed
EP-3846793-B1 EIF4E INHIBITORS AND USES THEREOF PIC THERAPEUTICS INC (US) 2024-01-24 — — EP disclosed
US-20220089587-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. 2022-03-24 — — US disclosed
CN-113164419-A EIF4E inhibitors and uses thereof 皮克医疗公司 2021-07-23 — — CN disclosed
EP-3846793-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. (US) 2021-07-14 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12030875-B2 EIF4E inhibitors and uses thereof EIF4E, EIF4EBP1, EIF4A1 KMT2A 1710/4885ALOX5 4250/4885LMNA 2297/4885
US-20220089587-A1 EIF4E INHIBITORS AND USES THEREOF EIF4E, EIF4EBP1, EEF2K KMT2A 1533/4885ALOX5 3543/4885LMNA 2618/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback